- Investing.com
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.
Metrics to compare | 068270 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship068270PeersSector | |
---|---|---|---|---|
P/E Ratio | 122.0x | 13.4x | −0.6x | |
PEG Ratio | −2.36 | 0.01 | 0.00 | |
Price/Book | 2.3x | 1.8x | 2.6x | |
Price / LTM Sales | 14.8x | 2.2x | 3.1x | |
Upside (Analyst Target) | 30.8% | 12.7% | 58.1% | |
Fair Value Upside | Unlock | 11.7% | 9.2% | Unlock |